Amylin is a different fullness hormone from GLP-1. Nicholas covers how cagrilintide works, the REDEFINE 1, 2 and 4 results, and where the CagriSema FDA review stands.
Read the full post: CagriSema and amylin: what's next after GLP-1s
In this episode
- 00:00 Cold open and intro
- 00:36 What amylin is
- 00:59 How it differs from GLP-1
- 01:11 The REDEFINE results
- 01:47 The head-to-head miss vs tirzepatide
- 02:03 Who might actually benefit
- 02:28 FDA filing and what's next
- 02:48 Wrap-up and Amino Club code
Peptides covered
Tools and deals
- Free reconstitution and dosing calculator: mypeps.info/calculator
- Amino Club: 40% off with code MYPEPSINFO at aminoclub.com
Sources
- https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916501
- https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2025/07/02/14/43/REDEFINE-1-and-REDEFINE-2
- https://pubmed.ncbi.nlm.nih.gov/34798060/
- https://www.biospace.com/press-releases/novo-nordisk-a-s-cagrisema-demonstrated-23-weight-loss-in-an-open-label-head-to-head-redefine-4-trial-in-people-with-obesity-the-primary-endpoint-was-not-achieved
- Full source list in the blog post.
Educational information only, not medical advice. Talk to a licensed clinician before starting, stopping or changing any medication. Research-grade peptides are not FDA-approved drugs.